MedPath

Efficacy Evaluation of the Activity of a Cosmetic Product (Topical Use) on Hair Regrowth vs Placebo

Not Applicable
Completed
Conditions
Hypertrichosis
Interventions
Other: Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)
Other: Placebo
Registration Number
NCT03273504
Lead Sponsor
Derming SRL
Brief Summary

Aim of the study is to evaluate clinically and by non-invasive instrumental evaluations the activity on hair regrowth of a topical cosmetic product versus placebo (comparison within subjects)

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
24
Inclusion Criteria
  • healthy volunteers
  • female sex
  • with hypertrichosis
  • agreeing not to perform epilation or scrub/peeling treatment on the test area (legs) during the week preceding the inclusion
  • good general state of health
Exclusion Criteria
  • pregnancy
  • lactation
  • subjects whose insufficient adhesion to the study protocol is foreseeable
  • sensitive skin
  • oral contraceptive therapy started less than 1 year
  • presence of varicose or capillary veins of surface
  • hormonal therapies able to influence hair growth.
  • presence of cutaneous disease on the tested area, as lesions, scars, malformations.
  • diabetes
  • endocrine disease
  • hepatic disorder
  • renal disorder
  • cardiac disorder
  • cancer.
  • farmacological topical treatment and surgery and/or medical treatment on the treated side performed in the last 3 months
  • systemic corticosteroids
  • aspirin or non-steroid anti-inflammatory drugs (FANS)
  • diuretic.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)Comparison within subjects of Actapil Corpo Spray versus Placebo. The study product will be applied twice a dayon the right or left leg (tibialis area) according to a randomisation list. The placebo product will be applied in the same way, on the controlateral leg.
Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)PlaceboComparison within subjects of Actapil Corpo Spray versus Placebo. The study product will be applied twice a dayon the right or left leg (tibialis area) according to a randomisation list. The placebo product will be applied in the same way, on the controlateral leg.
Primary Outcome Measures
NameTimeMethod
Change from baseline of the hair densityBaseline (T0), 1 month (T1), 3 months (T3)

Hair density (hair number/mm2) is calculate by Image-Pro Plus software on the microscopic images captured with Dino-Lite (AnMo Electronics Corporation,Taiwan)

Change from baseline of hair regrowth speedBaseline (T0), 1 month (T1), 3 months (T3)

Hair regrowth speed (mm/die) is calculate by Image-Pro Plus software on the microscopic images captured with Dino-Lite (AnMo Electronics Corporation,Taiwan)

Change from baseline of the percentage of terminal hairBaseline (T0), 1 month (T1), 3 months (T3)

Percentage of terminal hair (terminal hair has a diameter \>0.04 mm) is calculate by Image-Pro Plus software on the microscopic images captured with Dino-Lite (AnMo Electronics Corporation,Taiwan)

Change from baseline of the percentage of vellus hairBaseline (T0), 1 month (T1), 3 months (T3)

Percentage of vellus hair (terminal hair has a diameter \<0.04 mm) is calculate by Image-Pro Plus software on the microscopic images captured with Dino-Lite (AnMo Electronics Corporation,Taiwan)

Secondary Outcome Measures
NameTimeMethod
Change from baseline of superficial skin hydrationBaseline (T0), 1 month (T1), 3 months (T3)

Skin electrical capacitance value is measured with Corneometer CM825 (Courage - Khazaka, Köln, Germany).

The measure of the skin capacitance properties is an indirect expression of its hydration level.

Trial Locations

Locations (1)

DERMING

🇮🇹

Milano, MI, Italy

© Copyright 2025. All Rights Reserved by MedPath